Lactobacillus salivarius can make cancer immunotherapy less effective by producing indole-3-lactic acid (ILA), that weakens the body’s anti-tumor immune response.
Early interventions targeting the infant gut microbiota, especially in babies born by C-section, may reduce the probability of neurodevelopmental conditions such as autism.
Supplementation with key beneficial bacteria, alongside efforts to reduce breastfeeding barriers, may offer scalable strategies to reduce socioeconomic health disparities.
David Suissa, CEO of BYOME LABS, discusses the growing interest in microbiome research, from the gut and vaginal ecosystems to the less explored skin, scalp and oral microbiomes.
The presence of certain microbes was associated with major shifts in tumor gene activity and the immune environment around the cancer.
Julie Rodriguez, researcher at Inserm (National Institute of Health and Medical Research, France) explored the main categories of microbiome-based biomarkers and their potential applications in clinical practice.
Targeting the gut microbiota-ergothioneine pathway may offer a new way to prevent or treat cognitive side effects of antipsychotic drugs.
Supplementing creatine alongside specific gut bacteria such as Bifidobacterium could offer a treatment for depression by restoring brain energy metabolism.
Marta Ciechonska of Salient Bioscience presented the company’s approach to developing standardized, reproducible microbiome tests based on shotgun metagenomic sequencing.
Reducing dietary fat or controlling gut inflammation could help preserve immune cells and protect gut immunity, offering a strategy to prevent diet-related gut diseases.
